Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System

Abstract

Background Eosinophilic pneumonia (EP) is a rare adverse event caused by several types of drugs, such as antibiotics; however, its characteristics remain poorly described. This study aimed to analyze the disproportionality between the occurrence of EP and anti-methicillin-resistant Staphylococcus aureus (MRSA) agents and to characterize anti-MRSA agent-induced EP events using the Food and Drug Administration Adverse Event Reporting System (FAERS). Method Disproportionality linking EP and anti-MRSA agents was analyzed using Bayesian confidence propagation neural networks of information components and reporting odds ratio methodologies. The FAERS dataset for the fourth quarter of 2012 to the fourth quarter of 2022 was used. We also analyzed the characteristics of the case of EP induced by anti-MRSA agents. Results A total of 14,805,795 reports were obtained from FAERS. Disproportionality analysis revealed that the EP signal was detected only in cases with the administration of daptomycin (DAP). This disproportionality signal was consistently detected in the sensitivity analysis. Compared to other reports of DAP-related adverse events, the reports of DAP-related EP were characterized by male sex (odds ratio (OR): 1.94, 95% confidence interval (CI): 1.12–3.37), older age (>70 years; OR: 2.70, 95% CI: 1.68–4.33), and longer duration of treatment (over 21 days; OR: 5.08, 95% CI: 3.21–8.05). Conclusion This study revealed that among the anti-MRSA agents, disproportionality in the occurrence of EP was observed only with DAP. Our results suggest that sex, age, and treatment duration may affect the occurrence of DAP-induced EP. Clinicians should exercise caution regarding EP during DAP administration.